Focus on MBP epitope peptides: Analysis of central myelin damage markers and research tools in EAE models
Author: Senior Product Manager of UA Views：17 
This article systematically elucidates the physiological role of myelin basic protein (MBP) as a central nervous system-specific protein in maintaining myelin structural stability, and analyzes its clinical application value as a sensitive indicator and objective biochemical marker for brain injury in diseases such as acute traumatic brain injury, cerebral infarction, cerebral hemorrhage, and multiple sclerosis.
- Recent Advances
- Product Information
Recent Advances
Focus on MBP Epitope Peptide: Analysis of Central Myelin Damage Biomarkers and EAE Model Research Tools
Summary
This article systematically elaborates on the molecular characteristics and clinical significance of Myelin Basic Protein (MBP), highlighting its physiological function as a central nervous system-specific protein in maintaining myelin structural stability. It analyzes its clinical application value as a sensitive indicator of brain damage and an objective biochemical marker in diseases such as acute craniocerebral injury, cerebral infarction, cerebral hemorrhage, and multiple sclerosis.
This article systematically elaborates on the molecular characteristics and clinical significance of Myelin Basic Protein (MBP), highlighting its physiological function as a central nervous system-specific protein in maintaining myelin structural stability. It analyzes its clinical application value as a sensitive indicator of brain damage and an objective biochemical marker in diseases such as acute craniocerebral injury, cerebral infarction, cerebral hemorrhage, and multiple sclerosis.
I. Molecular Characteristics and Physiological Functions of MBP
Myelin Basic Protein (MBP) is a protein unique to the central nervous system, located on the cytoplasmic surface of myelin lipids and tightly bound to them. MBP plays an irreplaceable role in maintaining the structural and functional stability of central nervous system myelin, serving as the key molecular foundation for nerve fiber insulation and rapid signal conduction.
When the blood-brain barrier is compromised and its permeability altered, MBP can be released into the bloodstream, leading to elevated serum MBP levels. Therefore, changes in MBP levels can reflect the severity of oligodendrocyte myelin damage in white matter, serving as an objective biochemical indicator of central nervous system injury and acute demyelination.
II. Clinical Significance of MBP in Acute Central Nervous System Injury
In acute craniocerebral injury, serum MBP concentration in severe brain trauma is closely related to the severity of primary brain injury and the extent of intracranial lesions as reflected by CT. Studies confirm that higher MBP levels indicate worse prognosis, making MBP a specific marker for assessing the extent of brain trauma and prognosis. Animal trauma models show that lesions in the superficial cortex and periventricular areas release MBP into cerebrospinal fluid and blood more readily than deep cortical injuries, enabling MBP to assess nerve fiber density—a feature difficult to achieve with conventional CT or MRI.
In acute cerebral infarction, larger infarct areas and more severe conditions lead to more pronounced myelin necrosis in the ischemic core, resulting in higher MBP concentrations. After acute cerebral hemorrhage, serum MBP levels can reflect the extent of secondary brain injury. In brain tumors, both peritumoral edema volume and intracranial pressure are positively correlated with serum and cerebrospinal fluid MBP levels.
III. Diagnostic Value of MBP in Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease characterized by inflammatory demyelination in the central nervous system. Serum and cerebrospinal fluid MBP are specific biochemical markers reflecting central nervous system myelin loss. While healthy individuals show no detectable anti-MBP antibody proteins in peripheral blood, MS patients exhibit measurable levels. CSF MBP concentrations of 4-8 ng/mL may indicate chronic demyelination or post-acute recovery, while levels ≥9 ng/mL suggest active myelin destruction. The CSF MBP/CK-BB ratio has been proposed as a more specific demyelination index than MBP alone.
IV. Research Value of MBP (68-86) Epitope Peptide
MBP (68-86) is a peptide fragment corresponding to amino acid residues 68-86 of the MBP protein sequence. It serves as an autoantigen and immunogen in experimental autoimmune encephalomyelitis (EAE) animal models, widely used in studies of immune responses related to multiple sclerosis. Notably, the epitope corresponding to MBP (68-86) is not exposed in normal tissues but becomes recognizable by the immune system only when central nervous system myelin undergoes degenerative changes. This characteristic makes it a crucial target for studying autoimmune demyelination mechanisms and developing immune tolerance therapies.
V. Conclusion
As a myelin protein unique to the central nervous system, MBP levels in serum and cerebrospinal fluid show significant changes correlated with injury severity in acute craniocerebral injury, cerebral infarction, cerebral hemorrhage, and multiple sclerosis, serving as important objective biochemical markers for assessing myelin damage severity and prognosis. MBP (68-86), as a key antigenic epitope, plays an indispensable role as a research tool in EAE models and studies of multiple sclerosis immune mechanisms.
In MBP-related basic research and assay development, high-quality MBP (68-86) epitope peptides are essential tools for EAE model induction, autoantibody detection, and immune mechanism studies. To meet these research needs, Univ provides MBP (68-86), suitable for constructing EAE animal models, studying MBP-specific T-cell immune responses, and developing/validating MS-related autoantibody detection methods.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy 
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
